Early Improvement of Psychiatric Symptoms with Long-Acting Injectable Antipsychotic Predicts Subsequent Social Functional Remission in Patients with Schizophrenia

Takashi Ohnishi,1 Akihide Wakamatsu,1 Hisanori Kobayashi2 1Medical Affairs Division, Janssen Pharmaceutical K.K., Tokyo, Japan; 2Research and Development Clinical Science Division, Janssen Pharmaceutical K.K., Tokyo, JapanCorrespondence: Takashi OhnishiMedical Affairs Division, Janssen Pharmaceutica...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ohnishi T, Wakamatsu A, Kobayashi H
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	schizophrenia social function functional outcome long-acting injectable antipsychotics Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/84d177e2918d459cb0f96654651b1332
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:84d177e2918d459cb0f96654651b1332
record_format	dspace
spelling	oai:doaj.org-article:84d177e2918d459cb0f96654651b13322021-12-02T14:26:22ZEarly Improvement of Psychiatric Symptoms with Long-Acting Injectable Antipsychotic Predicts Subsequent Social Functional Remission in Patients with Schizophrenia1178-2021https://doaj.org/article/84d177e2918d459cb0f96654651b13322021-04-01T00:00:00Zhttps://www.dovepress.com/early-improvement-of-psychiatric-symptoms-with-long-acting-injectable--peer-reviewed-article-NDThttps://doaj.org/toc/1178-2021Takashi Ohnishi,1 Akihide Wakamatsu,1 Hisanori Kobayashi2 1Medical Affairs Division, Janssen Pharmaceutical K.K., Tokyo, Japan; 2Research and Development Clinical Science Division, Janssen Pharmaceutical K.K., Tokyo, JapanCorrespondence: Takashi OhnishiMedical Affairs Division, Janssen Pharmaceutical K.K., 5-2, Nishi-kanda 3-chome Chiyoda-ku, Tokyo, 101-0065, JapanTel +81-3-4411-7700Fax +81-3-4411– 5031Email tohnish8@its.jnj.comPurpose: The aim of this study was to clarify whether early symptomatic improvement in response to a long-acting injectable antipsychotic (LAI) contributes to subsequent social functional remission in patients with schizophrenia using the previous clinical trial data (EudraCT registration number: 2011-004889-15). Associations between other factors and social functional remission were also explored.Patients and Methods: We analyzed 428 patients with schizophrenia in which the personal and social performance scale (PSP) and the involvement evaluation questionnaire (IEQ) at the time of the base line were recorded. Social functional remission was defined as participants who scored PSP > 70 at the end of 65 weeks. Logistic regression analyses were done to examine associations between social functional remission and clinical and demographic characteristics including early symptomatic response evaluated by Positive and Negative Syndrome Scale (PANSS) at week one.Results: One hundred out of 428 patients showed social functional remission at the end of the observation period. Shorter duration of illness, higher baseline score of supervision evaluated by IEQ and higher baseline PSP were significantly associated with the social functional remission. Improvement of positive subscale of PANSS at one week was significantly associated with later social functional remission when baseline PSP scores were excluded from predictive variables.Conclusion: Shorter duration of illness, residual type of schizophrenia, higher baseline score of supervision and higher baseline social functioning were predictors of subsequent social functional remission. Although its effect seems to be limited, early symptomatic improvement could be also was a predictor of social functional remission.Keywords: schizophrenia, social function, functional outcome, long-acting injectable antipsychotics; LAIOhnishi TWakamatsu AKobayashi HDove Medical Pressarticleschizophreniasocial functionfunctional outcomelong-acting injectable antipsychoticsNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol Volume 17, Pp 1095-1104 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	schizophrenia social function functional outcome long-acting injectable antipsychotics Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	schizophrenia social function functional outcome long-acting injectable antipsychotics Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Ohnishi T Wakamatsu A Kobayashi H Early Improvement of Psychiatric Symptoms with Long-Acting Injectable Antipsychotic Predicts Subsequent Social Functional Remission in Patients with Schizophrenia
description	Takashi Ohnishi,1 Akihide Wakamatsu,1 Hisanori Kobayashi2 1Medical Affairs Division, Janssen Pharmaceutical K.K., Tokyo, Japan; 2Research and Development Clinical Science Division, Janssen Pharmaceutical K.K., Tokyo, JapanCorrespondence: Takashi OhnishiMedical Affairs Division, Janssen Pharmaceutical K.K., 5-2, Nishi-kanda 3-chome Chiyoda-ku, Tokyo, 101-0065, JapanTel +81-3-4411-7700Fax +81-3-4411– 5031Email tohnish8@its.jnj.comPurpose: The aim of this study was to clarify whether early symptomatic improvement in response to a long-acting injectable antipsychotic (LAI) contributes to subsequent social functional remission in patients with schizophrenia using the previous clinical trial data (EudraCT registration number: 2011-004889-15). Associations between other factors and social functional remission were also explored.Patients and Methods: We analyzed 428 patients with schizophrenia in which the personal and social performance scale (PSP) and the involvement evaluation questionnaire (IEQ) at the time of the base line were recorded. Social functional remission was defined as participants who scored PSP > 70 at the end of 65 weeks. Logistic regression analyses were done to examine associations between social functional remission and clinical and demographic characteristics including early symptomatic response evaluated by Positive and Negative Syndrome Scale (PANSS) at week one.Results: One hundred out of 428 patients showed social functional remission at the end of the observation period. Shorter duration of illness, higher baseline score of supervision evaluated by IEQ and higher baseline PSP were significantly associated with the social functional remission. Improvement of positive subscale of PANSS at one week was significantly associated with later social functional remission when baseline PSP scores were excluded from predictive variables.Conclusion: Shorter duration of illness, residual type of schizophrenia, higher baseline score of supervision and higher baseline social functioning were predictors of subsequent social functional remission. Although its effect seems to be limited, early symptomatic improvement could be also was a predictor of social functional remission.Keywords: schizophrenia, social function, functional outcome, long-acting injectable antipsychotics; LAI
format	article
author	Ohnishi T Wakamatsu A Kobayashi H
author_facet	Ohnishi T Wakamatsu A Kobayashi H
author_sort	Ohnishi T
title	Early Improvement of Psychiatric Symptoms with Long-Acting Injectable Antipsychotic Predicts Subsequent Social Functional Remission in Patients with Schizophrenia
title_short	Early Improvement of Psychiatric Symptoms with Long-Acting Injectable Antipsychotic Predicts Subsequent Social Functional Remission in Patients with Schizophrenia
title_full	Early Improvement of Psychiatric Symptoms with Long-Acting Injectable Antipsychotic Predicts Subsequent Social Functional Remission in Patients with Schizophrenia
title_fullStr	Early Improvement of Psychiatric Symptoms with Long-Acting Injectable Antipsychotic Predicts Subsequent Social Functional Remission in Patients with Schizophrenia
title_full_unstemmed	Early Improvement of Psychiatric Symptoms with Long-Acting Injectable Antipsychotic Predicts Subsequent Social Functional Remission in Patients with Schizophrenia
title_sort	early improvement of psychiatric symptoms with long-acting injectable antipsychotic predicts subsequent social functional remission in patients with schizophrenia
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/84d177e2918d459cb0f96654651b1332
work_keys_str_mv	AT ohnishit earlyimprovementofpsychiatricsymptomswithlongactinginjectableantipsychoticpredictssubsequentsocialfunctionalremissioninpatientswithschizophrenia AT wakamatsua earlyimprovementofpsychiatricsymptomswithlongactinginjectableantipsychoticpredictssubsequentsocialfunctionalremissioninpatientswithschizophrenia AT kobayashih earlyimprovementofpsychiatricsymptomswithlongactinginjectableantipsychoticpredictssubsequentsocialfunctionalremissioninpatientswithschizophrenia
_version_	1718391378817318912

Early Improvement of Psychiatric Symptoms with Long-Acting Injectable Antipsychotic Predicts Subsequent Social Functional Remission in Patients with Schizophrenia

Ejemplares similares